Modifying effect of arterial hypertension on amyotrophic lateral sclerosis

Abstract Given the high oxygen consumption of motor neurons, we sought to assess the frequency and prognostic value of arterial hypertension (affecting brain's oxygen supply) in amyotrophic lateral sclerosis (ALS). We consecutively and prospectively included all ALS patients with regular medical follow-up and documented blood pressure measurements and monitored them until death. Vascular factors diagnosed prior to the onset of motor signs in ALS patients were compared with those in a stratified, age- and gender-matched case-control population. The severity of leukoaraiosis on magnetic resonance imaging (MRI) was blindly assessed. Post mortem examinations were performed when authorized. Compared with controls (n = 408), the 102 ALS patients were significantly more likely to display hypertension (41–57%) and current smoking (15–26%). The number of years of hypertension was associated with survival (HR = 1.04 (1.01–1.07)). In a multivariate analysis, leukoaraiosis severity (HR = 1.214 (1.096–1.344)), current smoking (HR = 1.766 (1.085–2.872)) and low vital capacity (HR = 2.422 (1.266–4.633)) remained independent predictors of survival. Post mortem examinations revealed a greater frequency of leukoaraiosis in ALS patients (p = 0.02). In conclusion, the effect of chronic hypertension on survival might be exerted through abnormal neural perfusion. The higher frequency of recent hypertension in ALS patients may be due to a compensatory increase in blood pressure in response to a lower oxygen supply.

[1]  D. Arveiler,et al.  High blood pressure prevalence and control in a middle-aged French population and their associated factors: the MONA LISA study , 2011, Journal of hypertension.

[2]  P. Carmeliet,et al.  VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model , 2004, Nature.

[3]  L. Defebvre,et al.  Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[4]  M. Polkey,et al.  Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. , 2001, Brain : a journal of neurology.

[5]  Till Acker,et al.  Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration , 2001, Nature Genetics.

[6]  J. LaManna,et al.  Structural and functional adaptation to hypoxia in the rat brain , 2004, Journal of Experimental Biology.

[7]  A. Al-Chalabi,et al.  Early symptom progression rate is related to ALS outcome: a prospective population-based study. , 2002, Neurology.

[8]  T. Hanafusa,et al.  Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS , 2006, Neurology.

[9]  P. Carmeliet,et al.  VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death , 2003, Nature Genetics.

[10]  F. Fazekas,et al.  Prevalence of White Matter and Periventricular Magnetic Resonance Hyperintensities in Asymptomatic Volunteers , 1991 .

[11]  F. Norris,et al.  Onset, natural history and outcome in idiopathic adult motor neuron disease , 1993, Journal of the Neurological Sciences.

[12]  V. Sébille,et al.  Rural environment and risk factors of amyotrophic lateral sclerosis: a case–control study , 2010, Journal of Neurology.

[13]  G. Chatellier,et al.  Prevalence and Therapeutic Control of Hypertension in 30 000 Subjects in the Workplace , 2001, Hypertension.

[14]  A. Chiò,et al.  Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. , 2005, Brain : a journal of neurology.

[15]  L. Defebvre,et al.  CSF profiles of angiogenic and inflammatory factors depend on the respiratory status of ALS patients , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[16]  S. Harding Complications and consequences of obstructive sleep apnea , 2000, Current opinion in pulmonary medicine.

[17]  M Schumacher,et al.  A bootstrap resampling procedure for model building: application to the Cox regression model. , 1992, Statistics in medicine.

[18]  J. C. Torre,et al.  Evidence that Alzheimer’s disease is a microvascular disorder: the role of constitutive nitric oxide , 2000, Brain Research Reviews.

[19]  A. Eisen,et al.  Duration of amyotrophic lateral sclerosis is age dependent , 1993, Muscle & nerve.

[20]  D. Sautereau,et al.  Nutritional status is a prognostic factor for survival in ALS patients , 1999, Neurology.

[21]  H. Ehrenreich,et al.  Soccer, neurotrauma and amyotrophic lateral sclerosis: is there a connection? , 2004, Current medical research and opinion.

[22]  L. H. van den Berg,et al.  Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[23]  Sakurai,et al.  Expression of angiogenic factors in rabbit spinal cord after transient ischaemia , 1999, Neuropathology and applied neurobiology.

[24]  C. Visser,et al.  Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors , 1997, Journal of the Neurological Sciences.

[25]  T. Hanafusa,et al.  Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS , 2006, Neurology.

[26]  F. Clavel-Chapelon,et al.  Smoking and risk for amyotrophic lateral sclerosis: Analysis of the EPIC cohort , 2009, Annals of neurology.

[27]  Jack A. Taylor,et al.  VEGF PROMOTER HAPLOTYPE AND AMYOTROPHIC LATERAL SCLEROSIS (ALS) , 2004, Journal of neurogenetics.

[28]  C. Desnuelle,et al.  [Epidemiology of amyotrophic lateral sclerosis]. , 2009, Revue neurologique.

[29]  T D Koepsell,et al.  Prognosis in amyotrophic lateral sclerosis , 2003, Neurology.

[30]  A. Ludolph,et al.  Amyotrophic lateral sclerosis. , 2012, Current opinion in neurology.

[31]  Sleep disorders and diaphragmatic function in patients with amyotrophic lateral sclerosis. , 2000, American journal of respiratory and critical care medicine.

[32]  L. Defebvre,et al.  Deregulation of the hypoxia inducible factor-1α pathway in monocytes from sporadic amyotrophic lateral sclerosis patients , 2011, Neuroscience.

[33]  D. Leys,et al.  The impact of cerebral amyloid angiopathy on the occurrence of cerebrovascular lesions in demented patients with Alzheimer features: a neuropathological study , 2011, European journal of neurology.

[34]  S H Appel,et al.  Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. , 1995, Brain : a journal of neurology.

[35]  V. Meininger,et al.  SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype–phenotype correlations , 2010, Journal of Medical Genetics.

[36]  S. Bourke,et al.  Respiratory function vs sleep-disordered breathing as predictors of QOL in ALS , 2001, Neurology.

[37]  J. Iłżecka Cerebrospinal fluid vascular endothelial growth factor in patients with amyotrophic lateral sclerosis , 2004, Clinical Neurology and Neurosurgery.

[38]  Lorene M. Nelson,et al.  Epidemiology of ALS. , 1995, Clinical neuroscience.

[39]  D. Arveiler,et al.  Trends in plasma lipids, lipoproteins and dyslipidaemias in French adults, 1996-2007. , 2009, Archives of cardiovascular diseases.

[40]  A. Destée,et al.  Low levels of the vascular endothelial growth factor in CSF from early ALS patients , 2004, Neurology.

[41]  S. Ennis,et al.  ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis , 2006, Nature Genetics.

[42]  T. Perez Sclrose latrale amyotrophique (SLA) : valuation des fonctions ventilatoires , 2006 .